Contrasting Quoin Pharmaceuticals (NASDAQ:QNRX) and Apyx Medical (NASDAQ:APYX)

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) and Apyx Medical (NASDAQ:APYX – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Valuation & Earnings

This table compares Quoin Pharmaceuticals and Apyx Medical’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$9.38 million	($4.93)	-0.09
Apyx Medical	$44.16 million	4.71	-$23.18 million	($0.60)	-10.02

Quoin Pharmaceuticals has higher earnings, but lower revenue than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.1% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.6% of Apyx Medical shares are owned by institutional investors. 36.6% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 11.6% of Apyx Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Quoin Pharmaceuticals and Apyx Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	0	1	1	0	2.50
Apyx Medical	0	1	2	0	2.67

Quoin Pharmaceuticals presently has a consensus price target of $15.00, indicating a potential upside of 3,309.09%. Apyx Medical has a consensus price target of $6.33, indicating a potential upside of 5.38%. Given Quoin Pharmaceuticals’ higher probable upside, research analysts clearly believe Quoin Pharmaceuticals is more favorable than Apyx Medical.

Profitability

This table compares Quoin Pharmaceuticals and Apyx Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-169.43%	-76.78%
Apyx Medical	-46.93%	-51.04%	-37.12%

Risk and Volatility

Quoin Pharmaceuticals has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Summary

Apyx Medical beats Quoin Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Quoin Pharmaceuticals

(Get Rating)

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

About Apyx Medical

(Get Rating)

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.